Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM

Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM

Multiple myeloma (MM) remains incurable, and treatment of relapsed/refractory (R/R) disease is challenging. There is an unmet need for more targeted therapies in this setting; deep cellular and molecular phenotyping of the tumor and microenvironment in MM could help guide such therapies. This phase...

Full description

Bibliographic Details
Main Authors: Sandy Wong, Habib Hamidi, Luciano J. Costa, Selma Bekri, Natalia Neparidze, Ravi Vij, Tina G. Nielsen, Aparna Raval, Rajan Sareen, Elisabeth Wassner-Fritsch, Hearn J. Cho
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Immunology
Subjects:
atezolizumab
daratumumab
multiple myeloma
biomarkers
tumor microenvironment, multi-omics
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1085893/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1085893/full

Similar Items